Biohaven’s autoimmune drug disappoints investors in study of healthy volunteers
In a closely watched readout, Biohaven’s autoimmune disease treatment led to a 37% reduction on average in levels of harmful antibodies at the highest reported dose. But the reduction was not as high...
View ArticleArrowhead touts separate Phase 2b wins for RNAi treatments in mixed...
Arrowhead Pharmaceuticals is mulling what’s next for a pair of RNA interference therapies after reporting positive data from separate mid-stage trials in mixed hyperlipidemia. As RNAi treatments, both...
View ArticleAmgen nabs FDA approval for first Soliris interchangeable biosimilar
The FDA approved Amgen’s monoclonal antibody Bkemv as the first interchangeable biosimilar for Alexion’s blockbuster Soliris to treat two types of rare blood diseases, the agency announced late...
View ArticleBioNTech to increase mRNA vaccine footprint in Africa with $145M investment
Moderna may be holding back its plans for mRNA vaccine production in Africa, but Germany’s BioNTech is filling in the space with an expanded partnership with the Coalition for Epidemic Preparedness...
View ArticleClik here to view.
Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production
Two manufacturing tech developers have independently detailed their own approaches that could improve the cost and timelines to make cell and gene therapies and CAR-T products. On Wednesday, Ori...
View ArticleClik here to view.
Company developing video games for ADHD announces sale
A digital therapeutics pioneer is merging with another digital health company as the field, once flush with venture cash, struggles to find its place. Akili Interactive, a public company that develops...
View ArticleLilly's Retevmo lands new accelerated approval for pediatric cancers
The FDA on Wednesday granted another accelerated approval to Eli Lilly’s cancer drug Retevmo, this time for pediatric patients age 2 and older with certain types of thyroid cancer and solid tumors with...
View ArticleClik here to view.
FDA approves Tris Pharma's non-stimulant pediatric ADHD liquid medication
The FDA approved Tris Pharma’s Onyda XR to treat ADHD in children who are at least 6 years old. It’s the first liquid non-stimulant ADHD drug approved in the US, the company announced Wednesday, and...
View ArticleDollar General pulls mobile clinic mentions from website, partner no longer...
Has Dollar General quit its brief foray into healthcare services? The discount store chain, which launched a mobile healthcare clinic partnership in January 2023, appears to have removed mentions of...
View ArticleClik here to view.
Insurance upstart Clover Health launches new business selling its tech,...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The Medicare-focused health insurer Clover Health has launched a new venture to sell its technology...
View ArticleImmunovant postpones batoclimab readouts, maps path forward for second FcRn drug
Immunovant has reshuffled plans for two of its anti-FcRn antibody drugs. The company has delayed clinical readouts by several months for its late-stage FcRn inhibitor, called batoclimab, on the heels...
View ArticleBridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
BridgeBio released additional analyses of its Phase 3 study of acoramidis in ATTR-CM on Wednesday, spotlighting the link between serum transthyretin (TTR) levels and the drug’s long-term efficacy in...
View ArticleCinRx raises $73M to create more biotechs, further support obesity drug...
CinRx Pharma, the creator of biotechs like CinCor, which was acquired by AstraZeneca, raised another $73 million to support its current portfolio and launch startups to develop in-licensed drugs. The...
View ArticleExclusive: Plenful nabs $17M to automate pharmacy operations
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Plenful, a startup that wants to free pharmacists from burdensome back-office tasks, has raised $17...
View ArticleCompugen, Nxera disclose milestone payments; Insmed aims for $650M offering
Plus, news about Celcuity and Weave Bio: Compugen bags $5M milestone from AstraZeneca: The payment was triggered after the first lung cancer patient was dosed in a Phase 3 trial of AstraZeneca’s...
View ArticleFlush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1...
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for a wide range of diseases. The decision,...
View ArticleNovartis ends development of KRAS drug, citing 'increasing options available'
Novartis will stop developing a KRAS lung cancer drug that had made it to Phase 3 testing, a spokesperson confirmed to Endpoints News on Thursday. The experimental medicine, known as JDQ443 or...
View Article#ASCO24: The biopharma news we’re paying attention to
More than 40,000 people are expected to congregate in Chicago this week for the American Society of Clinical Oncology’s annual meeting, and an estimated 5,800 abstracts from drug companies and...
View ArticleClik here to view.
Doctors who endorse drugs on social media are often compensated, JAMA study...
Physicians who posted endorsements of drugs on social media often received cash payments from industry, and in some cases didn’t disclose that they had been compensated, a team of researchers found in...
View ArticleAlmac’s 2023 revenue bump; France to invest in easing greenhouse gas impact
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Almac reported a 14% increase in its revenue last year, reaching £958...
View Article